# Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

> **NCT00219284** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 359 (actual)

## Conditions studied

- Parkinson's Disease With End of Dose Wearing Off

## Interventions

- **DRUG:** Carbidopa/levodopa/entacapone

## Key facts

- **NCT ID:** NCT00219284
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219284, "Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00219284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*